## DECLARAT: N AND POWER OF A TORNEY

As a below named inventor, I hereb My residence, post office address an I believe I am the original, first and	d citizenship are as stated			joint inventor (if plural names
are listed below) of the subject matt	er which is claimed and for peptides, DNAs			
and Utilit	y of the polyp	encoding ch	e borabeber	
the specification of which is attache	d hereto unless the following	ng box is checked:		•
⊠ was filed on <u>February</u> Number <u>PCT/JP98/0079</u>	9 and was amended on		(if app	CT International Application licable).
hereby state that I have reviewed a any amendment referred to above.	and understand the content	s of the above-identifie	ed specification, includ	ing the claims, as amended by
acknowledge the duty to disclose in	formation of which is mat	erial to the patentabili	ty as defined in 37 CF	R § 1.56.
hereby claim foreign priority ben ertificate, or § 365(a) of any PCT In	ents under 35 U.S.C. § 11 sternational application wh	9(a)-(d) or § 365(b) of ich designated at least	any foreign applicati t one country other the	on(s) for patent or inventor's an United States, listed below
nd have also identified below, by pplication having a filing date before	checking the box, any fore	ign application for pa	tent or inventor's cert	tificate, or PCT International
rior Foreign Application(s)	te that of the application of	i which priority is clai	meu.	Priority Not Claimed
P. Hei. 9-43143	Japan	27/Febru	ary/1997	
(Number)	(Country)	(Day/Month	/Year Filed)	u
(Number)	(Country)	(Day/Month	Year Filed)	<b>.</b> .
(Number)	(Country)	(Day/Month	Year Filed)	<del></del>
hereby claim the benefits under 35	U.S.C. § 119(e) of any Un	ited States provisional	application(s) listed h	elow.
•				
(Application Number)	— (Filin	g Date)	4	
nereby claim the benefits under 3		-	) or £ 265(a) of any D	CT International application
signating the United States, listed ior United States or PCT Internati ity to disclose information which is the prior application and the natio	onal application in the mar material to patentability a	nner provided by the fits defined in 37 CFR § 1	rst paragraph of 35 Ú. l.56 which became ava	S.C. § 112, I acknowledge the
(Application Number)	(Fîlin	(Filing Date) (Status – patented, pending, aban		ed, pending, abandoned)
(Application Number)	(Filin	g Date)	(Status – patented, pending, abandoned)	
ereby appoint John H. Mion, Reg.	No. 18.879; Thomas J. Mac	peak, Reg. No. 19,292	Robert J. Seas, Jr., R	eg. No. 21.092; Darryl Mexic.
eg. No. 23,063; Robert V. Sloan, Reg. No. 24,861; Louis Gubinsky, Reg. 26,916; Joseph J. Ruch, Jr., Reg. ernstein, Reg. No. 25,665; Alan J. Kack, Reg. No. 30,951; Frank L. Berraniels, Reg. No. 32,562, Brian W. H. Neils, Reg. No. 33,102, Brett S. Suplication and to transact all busing out the application be addressed ashington, D.C. 20037.	g. No. 24,835; Neil B. Siege No. 26,577; Sheldon I. Lar asper, Reg. No. 25,426; Ken astein, Reg. No. 31,484; Ma annon, Reg. No. 32,778, Ab bylvester, Reg. No. 32,765 ess in the Patent and Trac to SUGHRUE, MION, 2	el, Reg. No. 25,200; Dandsman, Reg. No. 25,4 nneth J. Burchfiel, Reg rk Boland, Reg. No. 32 raham J. Rosner, Reg. and Robert M. Master demark Office connect ZINN, MACPEAK &	vid J. Cushing, Reg. N 30; Richard C. Turner c. No. 31,333; Gordon F c. 197; William H. Man No. 33,276; Bruce E. K s, Reg. No. 35,603; m; ed therewith, and req SEAS, PLLC, 2100 P	to. 28,703; John R. Inge, Reg., Reg. No. 29,710; Howard L. Kit, Reg. No. 30,764; Susan J. dir, Reg. No. 32,156; Scott M. ramer, Reg. No. 33,725; Paul y attorneys to prosecute this uest that all correspondence tennsylvania Avenue, N.W.,
ieved to be true; and further that this table by fine or imprisonment tements may jeopardize the validi	hese statements were made , or both, under Section	with the knowledge the with the Knowledge the with the wi	iat willful false statem e United States Code	ents and the like so made are
te Aug 10. 1999	Disco I	Hideaki	T	ADA
	rirst inventor	First Name		
0 1				
idenceOsaka,	Signature		Jado	
Japan	Post Office Address	c/o Minase Re	search Institu	ite, ONO Pharmaceuti
izenship Japan		Co I.td 1-		
•			***************************************	
te Aug 10. 1999	Second Inventor	Mikio	K	ONISHI
		First Name	Last N	lame =
sidence Osaka,		/hibin	Vais	
	Signature	ingu	) Consider	
Japan	Post Office Address	c/o Minase Re	search Institu	ite, ONO Pharmaceuti
tizenshin Japan		Co., Ltd., 1-	l, Sakurai 3-c	chome, Shimamoto-cho

		-		
Date Dug, 6, 1999	Third Inventor	Daikichi	FUKUSHIMA	
0		First Name	Last Name	
Residence Osaka,	Signature	Darbih.	Fuhrshime	_
		<sub>s</sub> c/o Minase Research		
•	•	Co., Ltd., 1-1, Sak	curai 3-chome, Sh	imamoto-cho
Citizenship Japan	=	Mishima-gun, OSAKA	618-8585 JAPAN	····
•		***************************************		***************************************
Date	Fourth Inventor	•		
		First Name	Last Name	
Residence	Signature		•	
-				<del>,</del>
Citizenship	<u> </u>			<del></del>
		***************************************		
Date	Fifth Inventor			
·		First Name	Last Name	
Residence	Signature			•
·				
	Post Office Address			
Sitizenship		***************************************		
	*****	***************************************	•••••••••••••••••••••••••••••••••••••••	***************************************
Date	Sixth Inventor			
		First Name	Last Name	
desidence	Signature			
				<del></del>
itizenship		•••••		
		***************************************	•••••••••••••••••••••••••••••••••••••••	••••••••••••
ate	_ Seventh Inventor			
		First Name	Last Name	
esidence	Signature			
			<del></del>	
tizenship			<del></del>	
			•••••••••••••••••••••••••••••••••••••••	
ate	Eighth Inventor			
		First Name	Last Name	
esidence	Signature			
				<del></del>
	Post Office Address		g g	
tizenshin			3	

## ASSIGNMENT

Whereas, I/We, Hideaki TADA, Mikio KONISHI and Daikichi FUKUSHIMA, all of Osaka, Japan X

hereinafter called assignor(s), have invented certain improvements in

Novel polypeptides, DNAs encoding the polypeptides, and Utility of the polypeptides

and executed an application for Letters Patent of the United States of America therefor on

1999: and August 10 & 6

ONO Pharmaceutical Co., Ltd. of Whereas,

> 1-5, Doshomachi 2-chome, Chuo-ku, Osaka-shi, OSAKA 541-0045 JAPAN

(assignee), desires to acquire the entire right, title and interest in the application and invention, and to any United States patents to be obtained therefor;

Now therefore, for valuable consideration, receipt whereof is hereby acknowledged.

I/We, the above named assignor(s), hereby sell, assign and transfer to the above named assignee, its successors and assigns, the entire right, title and interest in the application and the invention disclosed therein for the United States of America, including the right to claim priority under 35 U.S.C. § 119, and I/we request the Commissioner of Patents to issue any Letters Patent granted upon the invention set forth in the application to the assignee, its successors and assigns; and I/we will execute without further consideration all papers deemed necessary by the assignee in connection with the United States application when called upon to do so by the assignee.

i/we hereby authorize and re-	quest my attorneys SUGHRUE, MION, ZINN, N	IACPEAR & SEAS
of 2100 Pennsylvania Avenue, N.W.	, Washington, D.C. 20037-3202 to insert her	e in parentheses
(Application number	, filed	) the filing
date and application number of said	application when known.	
Date: Aug 10, 1999	s/ Hideaki Jada	
Date: Aug 10, 1999	s/ Aikio Konishi	
Date: Aug. 6. 1999	st Daible Frhishim	
Date:	s/	A Richard